Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Operating Revenue	15.66	-	-	0.18	-	0.03
Other Revenue	-	-	-	3.99	0.7	2.03
Revenue	15.66	-	-	4.17	0.7	2.07
Revenue Growth (YoY)	-	-	-	499.60%	-66.32%	-59.99%
Cost of Revenue	-1.07	-	-	11.02	4.32	4.02
Gross Profit	16.73	-	-	-6.85	-3.62	-1.96
Selling, General & Admin	8.08	8.47	8.91	5.28	4.23	3.35
Research & Development	9.12	9.32	12.65	-	-	-
Other Operating Expenses	-	-	-	-0	-0.15	-0.14
Operating Expenses	17.2	17.8	21.56	5.27	4.08	3.21
Operating Income	-0.47	-17.8	-21.56	-12.12	-7.7	-5.17
Interest Expense	-	-	-	-0.02	-1.07	-1.26
Interest & Investment Income	0.11	0.22	0.32	0.01	0	0.04
Currency Exchange Gain (Loss)	0.46	-0.21	0.31	0.25	0.81	-0.43
Other Non Operating Income (Expenses)	3.29	-	-	-2.59	-1.22	-1.01
EBT Excluding Unusual Items	3.38	-17.79	-20.93	-14.48	-9.18	-7.82
Gain (Loss) on Sale of Investments	2.21	2.21	-0.59	-	-	-
Gain (Loss) on Sale of Assets	-	-	-	-0	-0.02	0.12
Other Unusual Items	-	-	-	-0.65	2.54	3.54
Pretax Income	5.59	-15.58	-21.52	-15.12	-6.66	-4.16
Income Tax Expense	-0.24	-0.09	-0.14	-0.13	-0.14	-0.14
Earnings From Continuing Operations	5.83	-15.49	-21.38	-14.99	-6.52	-4.02
Earnings From Discontinued Operations	-	-	-	-	-	-0.9
Net Income	5.83	-15.49	-21.38	-14.99	-6.52	-4.91
Net Income to Common	5.83	-15.49	-21.38	-14.99	-6.52	-4.91
Shares Outstanding (Basic)	1,798	1,798	1,469	1,353	780	545
Shares Outstanding (Diluted)	1,798	1,798	1,469	1,353	780	545
Shares Change (YoY)	352.55%	22.39%	8.53%	73.52%	43.14%	4.52%
EPS (Basic)	0.00	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	0.00	-0.01	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	0.65	-14.68	-14.64	-14.99	-5.65	-2.7
Free Cash Flow Per Share	-	-0.01	-0.01	-0.01	-0.01	-0.01
Gross Margin	106.82%	-	-	-164.21%	-	-94.76%
Operating Margin	-3.00%	-	-	-290.62%	-1107.29%	-250.19%
Profit Margin	37.20%	-	-	-359.34%	-937.11%	-237.89%
Free Cash Flow Margin	4.16%	-	-	-359.30%	-812.46%	-130.70%
EBITDA	-0.02	-17.35	-21.23	-11.49	-7	-4.19
EBITDA Margin	-0.16%	-	-	-275.36%	-	-202.73%
D&A For EBITDA	0.45	0.45	0.33	0.64	0.7	0.98
EBIT	-0.47	-17.8	-21.56	-12.12	-7.7	-5.17
EBIT Margin	-3.00%	-	-	-290.62%	-	-250.19%

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q